Posted: 13 December 2011. Updated: 17 April 2012

Sayer, R. et al ( 2008) “The effect of stress on the expression of the amyloid precursor protein in rat brain” Neuroscience Letters, vol. 431, no. 3, pp: 197 - 200
Alzheimer´s Society (UK)
The study aimed to assess the effect of acute and repeated unavoidable stress exposure on two forms of protein (amyloid precursor protein - APP) in the normal rat brain. Twenty male rats were divided into four treatment groups; 20 days stress, 10 days stress, acute (1 day) stress and a control group. Stress was induced by placing individual animals on an "open elevated platform for 60 min". Animals were killed 24 hours after the last stress exposure (or handling in control animals) and their brains were removed for analysis.
Repetition
The authors note that "Previous studies in this laboratory have shown that a single exposure produces a marked increase in plasma corticosterone levels but animals develop tolerance to this effect between 10 and 20 daily sessions". They also state that the result of the current study "follows the previously published pattern of habituation of the plasma corticosterone response in rats treated with exactly the same protocol". These previously published findings, carried out by a number of the same authors demonstrate that animals have been used in repeated experiments. The study appears to be a repetition of previously conducted animal experiments of stress and APP.
Species differences and awareness of them
The authors do not acknowledge any species differences between rats and humans. The study uses healthy rats to research Alzheimer´s disease in humans. The authors don´t discuss the implications of this, nor the fact that rats do not get Alzheimer´s disease (1).
A study from 1989 studied differences between APP in humans and other species. The findings “may have implications for the mechanism of amyloid formation, since different species display different susceptibility to the formation of amyloid plaques". Highlighting that a large number of amyloid plaques are found in the cerebral cortex of Alzheimer´s patients, they note that these are "extremely rare in rats" (2)
Current available treatments
Although there is currently no cure for Alzheimer´s disease, there are a number of medications which may be prescribed to slow the development of the condition, depending on the severity of the disease. These work by, for example, preventing chemical breakdown in the brain. (3)
Animal suffering
The purpose of this study was to cause prolonged stress in the rats, so clearly they would have suffered as a result of the protocol - being placed on a raised platform with no ability to escape. The suffering was also prolonged, as tests lasted 60 minutes and continued for 10 or 20 days.
Alternative advanced techniques
These authors cite a paper in which it was found that, in human patients with Alzheimer-type dementia, higher plasma cortisol levels (associated with stress) were associated “with more rapid disease progression" (4) This can also be monitored as the disease progresses in human patients.
Poor experimental planning
This study used only male rats to study effects of stress on proteins in the brain. This ignores the fact that there are known to be differences between female and male rodent brains (5). These differences may influence the results obtained in this study.
The aim was to "determine whether exposure to acute and repeated stress affected the levels of the two primary forms of APP in the normal rat brain and whether this was regionally selective". However, following the findings that stress exposure appears to alter the processing of APP, the researchers compare their results to previous findings and conclude that “it is not clear whether this is due to changes in the release of corticosterone...or if it is due to the action of other neurontransmitters...that are altered following stress". It is therefore clear that this study did not elucidate the mechanisms of APP any further than is already known from previous research.
Disease context
Alzheimer´s disease usually affects people over 65, with an estimated 5-10% of this population being affected. 40% of the population over 85 years of age are also likely to be affected by the disease. Alzheimer´s is also the most common form of dementia and accounts for 50%-75% of the total. Nearly 18 million people live with dementia and this is expected to rise to 34 million people by 2025. (6)
References:
1.Turkington, C and Mitchell, D (2010) The Encyclopedia of Alzheimer´s Disease, Sheridan Books, USA http://books.google.co.uk/books?id=SA2X3ZHUZaEC&pg=PT170&lpg=PT170&dq=do+rats+naturally+get+alzheimer’s+disease&source=bl&ots=XPzJxgXH-F&sig=L3vdE4KNDUUhLVoE4255p2OQ7-s&hl=en&ei=-a2STrjAMouXhQeY39kN&sa=X&oi=book_result&ct=result&resnum=2&ved=0CCEQ6AEwAQ#v=onepage&q&f=false - accessed 10/10/11 ,
2.Anderson, J.P et al (1989) “Differential brain expression of the Alzheimer´s amyloid precursor protein” The EMBO Journal, vol. 8, no 12, pp:3627 - 3632 .
3.http://www.nhs.uk/Conditions/Alzheimers-disease/Pages/Treatment.aspx - accessed 04/10/11.
4.Csernansky, J. G et al (2006) “Plasma Cortisol and Progression of Dementia in Subjects With Alzheimer-Type Dementia” American Journal of Psychiatry, vol. 164, no, 12, pp:2164 - 2169.
5.Kurian, J. R et al (2010) “Sex Differences in Epigenetic Regulation of the Estrogen Receptor-α Promoter within the Developing Preoptic Area” Neuroendocrinology, vol. 151, no. 5, pp:2297 - 2305
6.Tanna, S (2004) Priority Medicines for Europe and the World
7."A Public Health Approach to Innovation” Background Paper, Alzheimer Disease “Opportunities to Address Pharmaceutical Gaps” archives.who.int/prioritymeds/report/background/alzheimer.doc - accessed 10/10/11